Dataset Information

Fenofibrate-mediated inhibition of tumor proliferation and progression by modulating the PTPN14/MARK/Hippo signaling axis

ABSTRACT: PTPN14 is a non-receptor tyrosine phosphatase that functions as a tumor suppressor through negative regulation of the Hippo signaling pathway, making it a potential therapeutic target for cancer. Despite its therapeutic potential, no PTPN14-targeting small-molecules have been developed to date. In this study, we discovered fenofibrate (FF), a small-molecule commonly used as a lipid-lowering agent, exhibits potent anti-proliferative and anti-migratory properties. Mechanistically, FF was found to directly bind the PPEY motif of PTPN14, facilitating formation of a complex with LATS1 and MARK3, which promotes cytoplasmic sequestration of YAP. Furthermore, genetic knockdown of PTPN14 or pharmacological inhibition of MARK3 substantially abolished the FF-mediated inhibition of malignant phenotypes, indicating the critical role of the PTPN14/MARK3/Hippo signaling axis in tumor progression. Notably, our data provide evidence for the potential of FF to sensitize the efficacy of conventional chemotherapeutics across melanoma, colorectal and ovarian carcinoma models. In conclusion, our results demonstrate that PTPN14 is a promising target for drug development in treating melanoma. These findings broaden our understanding of FF beyond its conventional functions, presenting a promising novel therapeutic strategy for treating melanoma.

ORGANISM(S): Mus musculus

PROVIDER: GSE301941 | GEO | 2026/07/10

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Pappalardo2016 - PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer This model is described in the article: Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. Pappalardo F, Russo G, Candido S, Pennisi M, Cavalieri S, Motta S, McCubrey JA, Nicoletti F, Libra M. PLoS ONE 2016; 11(3): e0152104 Abstract: Malignant melanoma is an aggressive tumor of the skin and seems to be resistant to current therapeutic approaches. Melanocytic transformation is thought to occur by sequential accumulation of genetic and molecular alterations able to activate the Ras/Raf/MEK/ERK (MAPK) and/or the PI3K/AKT (AKT) signalling pathways. Specifically, mutations of B-RAF activate MAPK pathway resulting in cell cycle progression and apoptosis prevention. According to these findings, MAPK and AKT pathways may represent promising therapeutic targets for an otherwise devastating disease.Here we show a computational model able to simulate the main biochemical and metabolic interactions in the PI3K/AKT and MAPK pathways potentially involved in melanoma development. Overall, this computational approach may accelerate the drug discovery process and encourages the identification of novel pathway activators with consequent development of novel antioncogenic compounds to overcome tumor cell resistance to conventional therapeutic agents. The source code of the various versions of the model are available as S1 Archive. This model is hosted on BioModels Database and identified by: MODEL1609190000. To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

Project description:This study was performed to evaluated RNA extraction and gene expression analysis of FFPE specimen stored for more than 20 years. Using long time stored FFPE material; large retrospective studies correlating molecular features with therapeutic response and clinical outcome, can be performed. Quantitative PCR (qPCR) was used to evaluate RNA extraction methods and to compare gene expression profiles of FFPE and fresh frozen (FF) tissue. Extracted RNA was subsequently subjected to microarray analysis and compared to qPCR data. The Ambion RecoverAll kit appears to be particularly suited for RNA extraction of long time stored FFPE tissues. Gene expression analysis using Affymetrix platform displayed a high degree of correlation for endogenous control genes comparing FF and FFPE tissues. We conclude that high quality gene expression signatures can be recognized using Affymetrix gene expression platform on FFPE tissue stored for more than 20 years. However, a general interpretation must be done with caution as different FFPE procedures have varying effects on RNA quality. Three RNA extraction methods from Roche (Basel, Switzerland), Ambion (Austin, TX, USA) and Qiagen (Hilden, Germany), designed for FFPE material was used. The methods were compared using qPCR. For the qPCR analysis, two different concentrations of input cDNA were used (20ng and 100ng) and 32 human endogenous control genes were examined. RNA from the Ambion FFPE kit was further analyzed by using microarray. Amplification of RNA prior to microarray analysis was performed using Nugen technologies (San Carlos, CA, USA). Nugen has developed amplification kits both for FFPE and FF materials: WT- ovation FFPE RNA amplification System V2 (Nugen FFPE), Ovation FF RNA Amplification System V2 (Nugen V2 FF) and Ovation FF Pico RNA Amplification System (Nugen PICO FF). The Nugen FFPE kit, designed for FFPE material was only used for FFPE tissue. The Nugen Pico FF kit, designed to target small amounts of FF RNA (>500 pg) and the Nugen V2 FF kit designed to target total FF RNA, were only used for FF tissue. Affymetrix standard amplification protocol (Affy FF) designed for FF RNA was also included as the standard method for amplification.

Dataset Information

Fenofibrate-mediated inhibition of tumor proliferation and progression by modulating the PTPN14/MARK/Hippo signaling axis

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets